Literature DB >> 9801926

Interleukin-10 increases mannose receptor expression and endocytic activity in monocyte-derived dendritic cells.

D Longoni1, L Piemonti, S Bernasconi, A Mantovani, P Allavena.   

Abstract

Human monocyte-derived dendritic cells were differentiated in vitro for 7 days with granulocyte macrophage-colony stimulating factor and interleukin-13. These cultured dendritic cells are at an immature stage of differentiation and exhert high endocytic activity via surface mannose receptor and via fluid-phase macropinocytosis. We have investigated the modulation of endocytosis by interleukin-10 in these cells. When added during the last 24 h of the 7-day culture, interleukin-10 significantly stimulated the uptake of fluorescein-labelled dextran (39 +/- 16% increase, mean +/- SD of 6 experiments), a sugar binding to the mannose receptor. This effect was dose dependent and correlated with the length of exposure to interleukin-10, with a maximal effect (more than seven-fold increase) when the cytokine was added at the beginning of the culture (day 0). The interleukin-10-increased fluorescein-labelled-dextran endocytosis was mostly mediated via the mannose receptor, as unlabelled mannose and specific antimannose receptor monoclonal antibody inhibited most of the uptake. Moreover, interleukin-10-treated cells expressed increased levels (up to four-fold) of mannose receptor. Interleukin-10 also increased, although to a lesser extent, the fluid-phase endocytosis (macropinocytosis) of fluorescein-labelled albumin. Interleukin-10 had the opposite effect on the differentiation and functional activity of monocyte-derived dendritic cells; cells having a very low stimulatory capacity and reduced expression of MHC class II and CD1a after a 7-day exposure. Thus interleukin-10 had a strong immunosuppressive effect on the differentiation and functional activity of monocyte-derived dendritic cells and yet strongly stimulated endocytosis in these cells. We speculate that an increased endocytic activity would eventually result in a decreased availability of antigens in the external milieu, thus contributing to the immunosuppressive and tolerogenic activity of interleukin-10.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9801926     DOI: 10.1007/s005990050037

Source DB:  PubMed          Journal:  Int J Clin Lab Res        ISSN: 0940-5437


  11 in total

1.  Mannose receptor induces T-cell tolerance via inhibition of CD45 and up-regulation of CTLA-4.

Authors:  Verena Schuette; Maria Embgenbroich; Thomas Ulas; Meike Welz; Jonas Schulte-Schrepping; Astrid M Draffehn; Thomas Quast; Katharina Koch; Melanie Nehring; Jessica König; Annegret Zweynert; Frederike L Harms; Nancy Steiner; Andreas Limmer; Irmgard Förster; Friederike Berberich-Siebelt; Percy A Knolle; Dirk Wohlleber; Waldemar Kolanus; Marc Beyer; Joachim L Schultze; Sven Burgdorf
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

Review 2.  Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine.

Authors:  Mauro Sousa de Almeida; Eva Susnik; Barbara Drasler; Patricia Taladriz-Blanco; Alke Petri-Fink; Barbara Rothen-Rutishauser
Journal:  Chem Soc Rev       Date:  2021-03-05       Impact factor: 54.564

3.  Enhanced expression of the mannose receptor by endothelial cells of the liver and spleen microvascular beds in the macrophage-deficient PU.1 null mouse.

Authors:  Sheena A Linehan; Roberta Weber; Scott McKercher; Ruth M Ripley; Siamon Gordon; Paul Martin
Journal:  Histochem Cell Biol       Date:  2005-05-24       Impact factor: 4.304

4.  Interleukin 10 promotes macrophage uptake of HDL and LDL by stimulating fluid-phase endocytosis.

Authors:  Diego Lucero; Promotto Islam; Lita A Freeman; Xueting Jin; Milton Pryor; Jingrong Tang; Howard S Kruth; Alan T Remaley
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2019-10-30       Impact factor: 4.698

5.  Regulation of human CD4(+) alphabeta T-cell-receptor-positive (TCR(+)) and gammadelta TCR(+) T-cell responses to Mycobacterium tuberculosis by interleukin-10 and transforming growth factor beta.

Authors:  R E Rojas; K N Balaji; A Subramanian; W H Boom
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

Review 6.  Exogenous control of the expression of Group I CD1 molecules competent for presentation of microbial nonpeptide antigens to human T lymphocytes.

Authors:  Angelo Aquino; Grazia Graziani; Ornella Franzese; Salvatore P Prete; Enzo Bonmassar; Laura Bonmassar; Stefania D'Atri
Journal:  Clin Dev Immunol       Date:  2011-03-22

7.  Secretory Leukoprotease Inhibitor (Slpi) Expression Is Required for Educating Murine Dendritic Cells Inflammatory Response Following Quercetin Exposure.

Authors:  Stefania De Santis; Vanessa Galleggiante; Letizia Scandiffio; Marina Liso; Eduardo Sommella; Anastasia Sobolewski; Vito Spilotro; Aldo Pinto; Pietro Campiglia; Grazia Serino; Angelo Santino; Maria Notarnicola; Marcello Chieppa
Journal:  Nutrients       Date:  2017-07-06       Impact factor: 5.717

8.  Re-expression of CD14 in Response to a Combined IL-10/TLR Stimulus Defines Monocyte-Derived Cells With an Immunoregulatory Phenotype.

Authors:  Sören Krakow; Marie L Crescimone; Charlotte Bartels; Verena Wiegering; Matthias Eyrich; Paul G Schlegel; Matthias Wölfl
Journal:  Front Immunol       Date:  2019-06-28       Impact factor: 7.561

9.  Establishing Porcine Monocyte-Derived Macrophage and Dendritic Cell Systems for Studying the Interaction with PRRSV-1.

Authors:  Helen Singleton; Simon P Graham; Katherine B Bodman-Smith; Jean-Pierre Frossard; Falko Steinbach
Journal:  Front Microbiol       Date:  2016-06-02       Impact factor: 5.640

10.  Early measurement of IL-10 predicts the outcomes of patients with acute respiratory distress syndrome receiving extracorporeal membrane oxygenation.

Authors:  Chia-Hsiung Liu; Shuenn-Wen Kuo; Wen-Je Ko; Pi-Ru Tsai; Shu-Wei Wu; Chien-Heng Lai; Chih-Hsien Wang; Yih-Sharng Chen; Pei-Lung Chen; Tze-Tze Liu; Shu-Chien Huang; Tzuu-Shuh Jou
Journal:  Sci Rep       Date:  2017-04-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.